Niger, M., Nichetti, F., Fornaro, L., Pircher, C., Morano, F., Palermo, F., . . . Mazzaferro, V. (2024). A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study. BMC cancer, 24(1), . https://doi.org/10.1186/s12885-024-12225-6
Chicago-Zitierstil (17. Ausg.)Niger, Monica, et al. "A Phase II/III Randomized Clinical Trial of CisPlatin PlUs Gemcitabine and Nabpaclitaxel (GAP) as PReoperative Chemotherapy Versus Immediate Resection in PatIents with ResecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study." BMC Cancer 24, no. 1 (2024). https://doi.org/10.1186/s12885-024-12225-6.
MLA-Zitierstil (9. Ausg.)Niger, Monica, et al. "A Phase II/III Randomized Clinical Trial of CisPlatin PlUs Gemcitabine and Nabpaclitaxel (GAP) as PReoperative Chemotherapy Versus Immediate Resection in PatIents with ResecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study." BMC Cancer, vol. 24, no. 1, 2024, https://doi.org/10.1186/s12885-024-12225-6.